Bone Biologics
BBLG
2 hedge funds and large institutions have $5.56K invested in Bone Biologics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 6 closing their positions.
0.18% less ownership
Funds ownership: 0.22% → 0.04% (-0.18%)
71% less funds holding
Funds holding: 7 → 2 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
98% less capital invested
Capital invested by funds: $235K → $5.56K (-$230K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.62K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$192K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.4K |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
-$11K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.05K |
| 5 |
VF
Virtu Financial
New York
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $5.54K | +$1.62K | +65 | +47% |
|
|
2
Wells Fargo
San Francisco,
California
| $19 | +$25 | +1 | New |
|
|
3
Walleye Capital
New York
| – | -$192K | -5,629 | Closed |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| – | -$11.4K | -334 | Closed |
|
|
5
MML Investors Services
Springfield,
Massachusetts
| – | -$11K | -313 | Closed |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$8.05K | -236 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$8K | -234 | Closed |
|
8
UBS Group
Zurich,
Switzerland
| – | -$96 | -3 | Closed |
|
BBLG Hedge Fund Activity: Q4 2023 in Review
2 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q4 2023, worth a combined $5.56K — down 98% from $235K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BBLG and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.62K. The largest seller was Walleye Capital, exiting entirely with an estimated $192K sold.
- 2 institutional investors held Bone Biologics (BBLG) as of Q4 2023, down from 7 in Q3 2023.
- Funds reported $5.56K of Bone Biologics stock for Q4 2023, down 98% quarter-over-quarter.
- 1 fund opened new Bone Biologics positions in Q4 2023 and 6 closed out, a net change of -5 holders.
- The largest Bone Biologics buyer in Q4 2023 was Tower Research Capital (TRC), an estimated $1.62K added.
- The largest Bone Biologics seller in Q4 2023 was Walleye Capital, an estimated $192K sold.
Based on aggregated 13F filings for Q4 2023.